Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers

References

• Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Internat Suppl. 2013;3(1):19–62.
   Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–886.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care. 2017 Jan;40(Suppl 1):S4–S5. PubMed PMID: 27979887.
   PubMedGoogle Scholar
• Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12–S154. PubMed PMID: 17276798.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837–853. PubMed PMID: 9742976.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854–865. PubMed PMID: 9742977.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129–139. PubMed PMID: 19092145.
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560–2572. PubMed PMID: 18539916.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 Aug 7;376(9739):419–430. PubMed PMID: 20594588; PubMed Central PMCID: PMCPMC4123233.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 May;28(2):103–117. PubMed PMID: 7587918.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–612. PubMed PMID: 19414839; PubMed Central PMCID: PMCPMC2763564.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Matsushita K, Ärnlöv J. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013 Sep 5;369(10):932–943. PubMed PMID: 24004120.
   Google Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014 Oct;37(10):2864–2883. PubMed PMID: 25249672; PubMed Central PMCID: PMCPMC4170131.
   PubMed Web of Science ®Google Scholar
• Robles NR, Villa J, Gallego RH. Non-proteinuric diabetic nephropathy. J Clin Med. 2015 Sep 7;4(9):1761–1773. PubMed PMID: 26371050; PubMed Central PMCID: PMCPMC4600158.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb ;39(2 Suppl 1): S1–S266. PubMed PMID: 11904577.
   PubMed Web of Science ®Google Scholar
• Speeckaert M, Van Biesen W, Delanghe J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014 Dec;29(12):2167–2177. PubMed PMID: 24470517.
   PubMed Web of Science ®Google Scholar
• Park SB, Kim SS, Kim IJ, et al. Variability in glycated albumin levels predicts the progression of diabetic nephropathy. J Diabetes Complicat. 2017 Jun;31(6):1041–1046. PubMed PMID: 28396158.
   PubMed Web of Science ®Google Scholar
• Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc. 2014 Nov;89(11):1564–1571. PubMed PMID: 25305751.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan;38(1):140–149. PubMed PMID: 25538310.
   PubMed Web of Science ®Google Scholar
• Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complicat. 2015 Mar;29(2):295–301. PubMed PMID: 25536866.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193–203. PubMed PMID: 18945920; PubMed Central PMCID: PMCPMC2606813.
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Bonomo K, et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2010 May;8(3):327–337. PubMed PMID: 19485923.
   PubMed Web of Science ®Google Scholar
• Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006 Mar;49(3):434–441. PubMed PMID: 16477438.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011 Jun;34(6):1431–1437. PubMed PMID: 21617112; PubMed Central PMCID: PMCPMC3114336.
   PubMed Web of Science ®Google Scholar
• Glucophage [prescribing information]. Princeton (NJ): Bristol-Myers Squibb Company; 2017.
   Google Scholar
• Kolterman OG, Gray RS, Shapiro G, et al. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984 Apr;33(4):346–354. PubMed PMID: 6423429.
   PubMed Web of Science ®Google Scholar
• Hampp C, Borders-Hemphill V, Moeny DG, et al. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37(5):1367–1374. PubMed PMID: 24623020.
   PubMed Web of Science ®Google Scholar
• Gliclazide. Summary of product characteristics; [cited 2018 Feb 26]. Available from: https://www.medicines.org.uk/emc/product/5883/smpc
   Google Scholar
• Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015 Aug 12;11(4):840–848. PubMed PMID: 26322096; PubMed Central PMCID: PMCPMC4548036.
   PubMed Web of Science ®Google Scholar
• Glucotrol [prescribing information]. New York (NY): Pfizer; 2016.
   Google Scholar
• Roussel R, Lorraine J, Rodriguez A, et al. Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease. Adv Ther. 2015 Nov;32(11):1029–1064. PubMed PMID: 26581749.
   PubMed Web of Science ®Google Scholar
• Amaryl [prescribing information]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2013.
   Google Scholar
• Diaβeta [prescribing information]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2009.
   Google Scholar
• Devineni D, Walter YH, Smith HT, et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol. 2003 Feb;43(2):163–170. PubMed PMID: 12616669.
   PubMed Web of Science ®Google Scholar
• Hasslacher C, Multinational Repaglinide Renal Study G. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003 Mar;26(3):886–891. PubMed PMID: 12610054.
   PubMed Web of Science ®Google Scholar
• Starlix [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2017.
   Google Scholar
• Nagai T, Imamura M, Iizuka K, et al. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003 Mar;59(3):191–194. PubMed PMID: 12590015.
   PubMed Web of Science ®Google Scholar
• Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001 May;57(2):147–152. PubMed PMID: 11417447.
   PubMed Web of Science ®Google Scholar
• Prandin [prescribing information]. Plainsboro (NJ): Novo Nordisk Inc; 2017.
   Google Scholar
• Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002 Mar-Apr;18(Suppl 2):S10–5. PubMed PMID: 11921433.
   PubMedGoogle Scholar
• Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol. 2003 Apr;55(4):368–374. PubMed PMID: 12680885; PubMed Central PMCID: PMCPMC1884238.
   PubMed Web of Science ®Google Scholar
• Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000 Jul;28(7):772–780. PubMed PMID: 10859151.
   PubMed Web of Science ®Google Scholar
• Actos [prescribing information]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2016.
   Google Scholar
• Avandia [prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; 2007.
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–2471. PubMed PMID: 17517853.
   PubMed Web of Science ®Google Scholar
• Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016 Mar 30;352:i1541. PubMed PMID: 27029385; PubMed Central PMCID: PMCPMC4816602.
   PubMed Web of Science ®Google Scholar
• Filipova E, Uzunova K, Kalinov K, et al. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther. 2017 Aug;8(4):705–726. PubMed PMID: 28623552; PubMed Central PMCID: PMCPMC5544610.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA drug safety communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines; [cited 2017 Dec 20]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm376389.htm
   Google Scholar
• Meloni AR, DeYoung MB, Lowe C, et al. GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013 Jan;15(1):15–27. PubMed PMID: 22776039; PubMed Central PMCID: PMCPMC3556522.
   PubMed Web of Science ®Google Scholar
• Trulicity [prescribing information]. Indianapolis (IN): Eli Lilly and Company; 2017.
   Google Scholar
• Tanzeum [prescribing information]. Wilmington (DE): GlaxoSmithKline LLC; 2016.
   Google Scholar
• Ozempic [prescribing information]. Bagsvaerd: Novo Nordisk Inc; 2017.
   Google Scholar
• Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009 Dec;68(6):898–905. PubMed PMID: 20002084; PubMed Central PMCID: PMCPMC2810801.
   PubMed Web of Science ®Google Scholar
• Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017 Nov;56(11):1381–1390. PubMed PMID: 28349386.
   PubMed Web of Science ®Google Scholar
• Young MA, Wald JA, Matthews JE, et al. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide. Postgrad Med. 2014 May;126(3):35–46. PubMed PMID: 24918790.
   PubMed Web of Science ®Google Scholar
• Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31–41. PubMed PMID: 28323117.
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007 Sep;64(3):317–327. PubMed PMID: 17425627; PubMed Central PMCID: PMCPMC2000650.
   PubMed Web of Science ®Google Scholar
• Byetta [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2015.
   Google Scholar
• US Food and Drug Administration. Drug safety information for healthcare professionals-information for healthcare professionals: reports of altered kidney function in patients using exenatide (marketed as Byetta). Washington (DC); 2009 [cited 2017 Jul 28]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm
   Google Scholar
• Victoza [prescribing information]. Plainsboro (NJ): Novo Nordisk Inc; 2016.
   Google Scholar
• Adlyxin [prescribing information]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2016.
   Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251–260. PubMed PMID: 28110911.
   PubMed Web of Science ®Google Scholar
• Dey J. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. Postgrad Med. 2017 May;129(4):409–420. PubMed PMID: 28322073.
   PubMed Web of Science ®Google Scholar
• Nesina [prescribing information]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2016.
   Google Scholar
• Onglyza [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2017.
   Google Scholar
• Januvia [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc; 2017.
   Google Scholar
• Tradjenta [prescribing information]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2017.
   Google Scholar
• Vildagliptin. Summary of product characteristics; [cited 2018 Feb 26]. Available from: https://www.medicines.org.uk/emc/product/6225/smpc
   Google Scholar
• Jardiance [prescribing information]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2016.
   Google Scholar
• Invokana [prescribing information]. Titusville (NJ): Janssen Pharmaceuticals, Inc; 2016.
   Google Scholar
• Farxiga [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2017.
   Google Scholar
• US Food and Drug Administration. Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings; [cited 2017 Jul 28]. Available from: https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm506554.htm
   Google Scholar
• Desai M, Yavin Y, Balis D, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jun;19(6):897–900. PubMed PMID: 28083972; PubMed Central PMCID: PMCPMC5485046.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Jun 12. PubMed PMID: 28605608.
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR); [cited 2017 Aug 16]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Silver Spring (MD): Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes; 2008.
   Google Scholar
• McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015 Nov;17(11):1085–1092. PubMed PMID: 26250051.
   PubMed Web of Science ®Google Scholar
• Bekiari E, Rizava C, Athanasiadou E, et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016 Jun;52(3):458–480. PubMed PMID: 26714458.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010 Jun;12(6):485–494. PubMed PMID: 20518804.
   PubMed Web of Science ®Google Scholar
• Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017 Oct;19(10):1473–1478. PubMed PMID: 28338281.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322. PubMed PMID: 27295427; PubMed Central PMCID: PMCPMC4985288.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016 Feb;39(2):222–230. PubMed PMID: 26681713.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017 Aug 31;377(9):839–848. PubMed PMID: 28854085.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834–1844. PubMed PMID: 27633186.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247–2257. PubMed PMID: 26630143.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017 Sep 28;377(13):1228–1239. PubMed PMID: 28910237.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Heilmann C, Hoogwerf BJ, et al. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis. 2013 Aug;62(2):396–398. PubMed PMID: 23684754.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Botros FT, Atisso CM, et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016 Feb 24;15:38. PubMed PMID: 26912057; PubMed Central PMCID: PMCPMC4765050.
   PubMed Web of Science ®Google Scholar
• Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015 Sep;3(9):697–703. PubMed PMID: 26276240.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus; [cited 2017 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT02465515
   Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2017 Jun 1. PubMed PMID: 28573765.
   Web of Science ®Google Scholar
• Cooper ME, Perkovic V, McGill JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015 Sep;66(3):441–449. PubMed PMID: 25960304.
   PubMed Web of Science ®Google Scholar
• Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016 Dec;39(12):2304–2310. PubMed PMID: 27742728.
   PubMed Web of Science ®Google Scholar
• Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. PubMed PMID: 28636754.
   PubMed Web of Science ®Google Scholar
• Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1): 69–73. PubMed PMID: 21206136.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Neubacher D, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015 May 21;14:57. PubMed PMID: 25990013; PubMed Central PMCID: PMCPMC4465456.
   PubMed Web of Science ®Google Scholar
• Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care. 2015 Apr;38(4):696–705. PubMed PMID: 25552421.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jul 16;373(3):232–242. PubMed PMID: 26052984.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Van de Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016 May 1;1(2):126–135. PubMed PMID: 27437883.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317–1326. PubMed PMID: 23992601.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327–1335. PubMed PMID: 23992602.
   PubMed Web of Science ®Google Scholar
• Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013 Nov;36(11):3460–3468. PubMed PMID: 24026560; PubMed Central PMCID: PMCPMC3816860.
   PubMed Web of Science ®Google Scholar
• Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the Cardiovascular Outcome Trial of Linagliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res. 2015 May;12(3):164–174. PubMed PMID: 25780262; PubMed Central PMCID: PMCPMC4390606.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017 Jan;40(1):69–76. PubMed PMID: 27797925.
   PubMed Web of Science ®Google Scholar
• Kawasaki I, Hiura Y, Tamai A, et al. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J Diabetes. 2015 Jan;7(1):41–46. PubMed PMID: 24661437.
   PubMed Web of Science ®Google Scholar
• Mori H, Okada Y, Arao T, et al. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014 May 4;5(3):313–319. PubMed PMID: 24843780; PubMed Central PMCID: PMCPMC4020336.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):323–334. PubMed PMID: 27299675.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128. PubMed PMID: 26378978.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Johnsson K, et al. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391–400. PubMed PMID: 26894924.
   PubMed Web of Science ®Google Scholar
• Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016 Feb 19;15:37. PubMed PMID: 26895767; PubMed Central PMCID: PMCPMC4761166.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Iwanaga Y, Miyaji Y, et al. Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up. Cardiovasc Diabetol. 2016 Mar 31;15:54. PubMed PMID: 27036865; PubMed Central PMCID: PMCPMC4818390.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Effect of LIXIsenatide on the renal system (ELIXIRS); [cited 2017 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT02276196
   Google Scholar
• ClinicalTrials.gov. Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA); [cited 2017 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT01897532
   Google Scholar
• ClinicalTrials.gov. Evaluation of the effects of Canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE); [cited 2017 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT02065791
   Google Scholar
• ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58); [cited 2017 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534
   Google Scholar